Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

Author(s): Aquilante CL

Abstract

The sulfonylureas stimulate insulin release from pancreatic beta cells, and have been a cornerstone of Type 2 diabetes pharmacotherapy for over 50 years. Although sulfonylureas are effective antihyperglycemic agents, interindividual variability exists in drug response (i.e., pharmacodynamics), disposition (i.e., pharmacokinetics) and adverse effects. The field of pharmacogenomics has been applied to sulfonylurea clinical studies in order to elucidate the genetic underpinnings of this response variability. Historically, most studies have sought to determine the influence of polymorphisms in drug-metabolizing enzyme genes on sulfonylurea pharmacokinetics in humans. More recently, polymorphisms in sulfonylurea drug target genes and diabetes risk genes have been implicated as important determinants of sulfonylurea pharmacodynamics in patients with Type 2 diabetes. As such, the purpose of this review is to discuss sulfonylurea pharmacogenomics in the setting of Type 2 diabetes, specifically focusing on polymorphisms in drug target and diabetes risk genes, and their relationship with interindividual variability in sulfonylurea response and adverse effects.

Similar Articles

Type 2 diabetes: principles of pathogenesis and therapy

Author(s): Stumvoll M, Goldstein BJ, van Haeften TW

Alternative therapies for type 2 diabetes

Author(s): Dey L, Attele AS, Yuan CS

Brussels, Belgium: International Diabetes Federation

Author(s): International Diabetes Federation

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Author(s): Wild S, Roglic G, Green A, Sicree R, King H

Prevalence of diabetes in Pakistan

Author(s): Shera AS, Jawad F, Maqsood A

Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53: 2504-2508

Author(s): Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, et al.

A narrative insight to maturity-onset diabetes of the young

Author(s): Kanwal SF, Fazal S, Muhammad Ismail, Nighat Naureen

[MODY type diabetes: overview and recent findings]

Author(s): Ben Khelifa S, Barboura I, Dandana A, Ferchichi S, Miled A

HLA-A, -B, and -DR associations in type 1 diabetes mellitus with onset after age forty

Author(s): Pittman WB, Acton RT, Barger BO, Bell DS, Go RC, et al.

Latent autoimmune diabetes in adults (LADA) should be less latent

Author(s): Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, et al.

Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes

Author(s): Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, et al.

Genetics of type 2 diabetes

Author(s): Owen KR, McCarthy MI

The emerging genetic architecture of type 2 diabetes

Author(s): Doria A, Patti ME, Kahn CR

Genome-wide association studies in type 2 diabetes

Author(s): McCarthy MI, Zeggini E

Type 2 diabetes: new genes, new understanding

Author(s): Prokopenko I, McCarthy MI, Lindgren CM

Type 2 Diabetes Genetics: Beyond GWAS

Author(s): Sanghera DK, Blackett PR

A genome-wide association study identifies novel risk loci for type 2 diabetes

Author(s): Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al.

Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels

Author(s): Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, et al.

A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants

Author(s): Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al.

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

Author(s): Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, et al.

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity

Author(s): Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al.

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis

Author(s): Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al.

Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci

Author(s): Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, et al.

Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes

Author(s): Silander K, Mohlke KL, Scott LJ, Peck EC, Hollstein P, et al.

Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution

Author(s): Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, et al.

Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort

Author(s): van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van Haeften TW, et al.

Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study

Author(s): van Hoek M, Dehghan A, Witteman JC, van Duijn CM, Uitterlinden AG, et al.

Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus

Author(s): Maeda S, Tsukada S, Kanazawa A, Sekine A, Tsunoda T, et al.

Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus

Author(s): Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, et al.

Inflammatory markers and risk of developing type 2 diabetes in women

Author(s): Hu FB, Meigs JB, Li TY, Rifai N, Manson JE

Therapy with oral antidiabetic drugs: applied pharmacogenetics

Author(s): Holstein A, Seeringer A, Kovacs P

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

Author(s): Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, et al.

Pharmacogenetics of Anti-Diabetes Drugs

Author(s): Distefano JK, Watanabe RM

Pharmacogenetics of oral antidiabetic treatment

Author(s): Schroner Z, Javorsky M, Kozarova M, Tkac I

Genetic basis of type 2 diabetes mellitus: implications for therapy

Author(s): Wolford JK, Vozarova de Courten B